Jefferies lowered the firm’s price target on Heron Therapeutics (HRTX) to $5 from $6 and keeps a Buy rating on the shares. Zynrelef delivered Q3 net revenue of $9.3M, ahead of the consensus view of $9M, driven by rising demand, vial access needle transition, improved access, and enhanced support programs, the analyst tells investors in a research note. The firm added that its price target which is based on a DCF valuation model, is also driven by oncology franchise sales, with peak sales of $106M in 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential
- Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
- Heron Therapeutics reports Q3 EPS (10c), consensus (1c)
- Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M
- HRTX Upcoming Earnings Report: What to Expect?